Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP.Centre-Université de Paris, Paris, France.
Institut Cochin, Inserm U1016, CNRS UMR8104, Université de Paris, CARPEM, Paris, France.
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1367-e1373. doi: 10.1210/clinem/dgab894.
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the tumor suppressor gene MEN1. The uncertainty of pathogenicity of MEN1 variants complexifies the selection of the patients likely to benefit from specific care.
MEN1-mutated patients should be offered tailored tumor screening and genetic counseling. We present a patient with hyperparathyroidism for whom genetic analysis identified a variant of uncertain significance in the MEN1 gene (NM_130799.2): c.654G > T p.(Arg218=). Additional functional genetic tests were performed to classify the variant as pathogenic and allowed prenatal testing.
Targeted next generation sequencing identified a synonymous variant in the MEN1 gene in a 26-year-old male with symptomatic primary hyperparathyroidism. In silico and in vitro genetic tests were performed to assess variant pathogenicity.
Genetic testing of the proband's unaffected parents showed the variant occurred de novo. Transcript study showed a splicing defect leading to an in-frame deletion. The classification of the MEN1 variant as pathogenic confirmed the diagnosis of MEN1 and recommended an adapted medical care and follow-up. Pathogenic classification also allowed to propose a genetic counseling to the proband and his wife. Noninvasive prenatal diagnosis was performed with a personalized medicine-based protocol by detection of the paternally inherited variant in maternal plasmatic cell free DNA, using digital PCR.
We showed that functional genetic analysis can help to assess the pathogenicity of a MEN1 variant with crucial consequences for medical care and genetic counseling decisions.
多发性内分泌肿瘤 1 型(MEN1)是一种常染色体显性疾病,由肿瘤抑制基因 MEN1 中的突变引起。MEN1 变异的致病性不确定,这使得选择可能受益于特定治疗的患者变得复杂。
MEN1 突变的患者应接受个性化的肿瘤筛查和遗传咨询。我们报告了一例甲状旁腺功能亢进症患者,其基因分析在 MEN1 基因(NM_130799.2)中发现了一个意义未明的变异:c.654G>T p.(Arg218=)。进行了额外的功能基因检测,以将该变异分类为致病性,并允许进行产前检测。
靶向下一代测序在一名 26 岁有症状的原发性甲状旁腺功能亢进症男性中发现了 MEN1 基因中的同义变异。进行了体外和体外遗传检测,以评估变异的致病性。
对先证者未受影响的父母进行基因检测,发现该变异是新生的。转录研究显示存在剪接缺陷,导致框架内缺失。MEN1 变异的致病性分类证实了 MEN1 的诊断,并建议进行适应性医疗护理和随访。致病性分类还允许对先证者及其妻子进行遗传咨询。通过基于个性化医学的方案,通过检测母体外周血循环无细胞 DNA 中的父系遗传变异,使用数字 PCR 进行了非侵入性产前诊断。
我们表明,功能基因分析有助于评估 MEN1 变异的致病性,这对医疗护理和遗传咨询决策具有重要意义。